Tert-butyl N-[1-[(3aR,4R,6R,6aR)-6-ethyl-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]-6-iodopyrazolo[5,4-d]pyrimidin-4-yl]-N-cyclopentylcarbamate;tert-butyl N-[1-[(3aR,4R,6R,6aR)-6-ethyl-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]-6-[3-(oxan-2-yloxy)prop-1-ynyl]pyrazolo[5,4-d]pyrimidin-4-yl]-N-cyclopentylcarbamate
C56H79IN10O12 — CID 158318793
Data last refreshed: (MolForge compound catalog, from PubChem)
About Tert-butyl N-[1-[(3aR,4R,6R,6aR)-6-ethyl-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]-6-iodopyrazolo[5,4-d]pyrimidin-4-yl]-N-cyclopentylcarbamate;tert-butyl N-[1-[(3aR,4R,6R,6aR)-6-ethyl-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]-6-[3-(oxan-2-yloxy)prop-1-ynyl]pyrazolo[5,4-d]pyrimidin-4-yl]-N-cyclopentylcarbamate
Tert-butyl N-[1-[(3aR,4R,6R,6aR)-6-ethyl-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]-6-iodopyrazolo[5,4-d]pyrimidin-4-yl]-N-cyclopentylcarbamate;tert-butyl N-[1-[(3aR,4R,6R,6aR)-6-ethyl-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]-6-[3-(oxan-2-yloxy)prop-1-ynyl]pyrazolo[5,4-d]pyrimidin-4-yl]-N-cyclopentylcarbamate (PubChem CID 158318793) has the molecular formula C56H79IN10O12 and a molecular weight of 1211.21 g/mol. Its IUPAC name is tert-butyl N-[1-[(3aR,4R,6R,6aR)-6-ethyl-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]-6-iodopyrazolo[5,4-d]pyrimidin-4-yl]-N-cyclopentylcarbamate;tert-butyl N-[1-[(3aR,4R,6R,6aR)-6-ethyl-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]-6-[3-(oxan-2-yloxy)prop-1-ynyl]pyrazolo[5,4-d]pyrimidin-4-yl]-N-cyclopentylcarbamate.
Molecular Properties
| Compound Name | Tert-butyl N-[1-[(3aR,4R,6R,6aR)-6-ethyl-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]-6-iodopyrazolo[5,4-d]pyrimidin-4-yl]-N-cyclopentylcarbamate;tert-butyl N-[1-[(3aR,4R,6R,6aR)-6-ethyl-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]-6-[3-(oxan-2-yloxy)prop-1-ynyl]pyrazolo[5,4-d]pyrimidin-4-yl]-N-cyclopentylcarbamate |
|---|---|
| PubChem CID | 158318793 |
| Molecular Formula | C56H79IN10O12 |
| Molecular Weight | 1211.21 g/mol |
| Exact Mass | 1210.49 |
| IUPAC Name | tert-butyl N-[1-[(3aR,4R,6R,6aR)-6-ethyl-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]-6-iodopyrazolo[5,4-d]pyrimidin-4-yl]-N-cyclopentylcarbamate;tert-butyl N-[1-[(3aR,4R,6R,6aR)-6-ethyl-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]-6-[3-(oxan-2-yloxy)prop-1-ynyl]pyrazolo[5,4-d]pyrimidin-4-yl]-N-cyclopentylcarbamate |
| SMILES | CC[C@H]1O[C@@H](n2ncc3c(N(C(=O)OC(C)(C)C)C4CCCC4)nc(C#CCOC4CCCCO4)nc32)[C@@H]2OC(C)(C)O[C@@H]21.CC[C@H]1O[C@@H](n2ncc3c(N(C(=O)OC(C)(C)C)C4CCCC4)nc(I)nc32)[C@@H]2OC(C)(C)O[C@@H]21 |
| InChI | InChI=1S/C32H45N5O7.C24H34IN5O5/c1-7-22-25-26(43-32(5,6)42-25)29(41-22)37-28-21(19-33-37)27(36(20-13-8-9-14-20)30(38)44-31(2,3)4)34-23(35-28)15-12-18-40-24-16-10-11-17-39-24;1-7-15-16-17(34-24(5,6)33-16)20(32-15)30-19-14(12-26-30)18(27-21(25)28-19)29(13-10-8-9-11-13)22(31)35-23(2,3)4/h19-20,22,24-26,29H,7-11,13-14,16-18H2,1-6H3;12-13,15-17,20H,7-11H2,1-6H3/t22-,24?,25-,26-,29-;15-,16-,17-,20-/m11/s1 |
| InChIKey | GOOYGIGKNHOBEJ-UJKRIJTQSA-N |
| XLogP | 10.18 |
| TPSA | 220.12 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 20 |
| Rotatable Bonds | 10 |
| Heavy Atoms | 79 |
| Complexity | — |
Lipinski Rule of Five
3 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 1211.21 |
| LogP ≤ 5 | 10.18 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 20 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'iodine', 'substructure': 'N/A'}, {'alert_name': 'triple_bond', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 158318793 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.